I doubt there will be any impact on grey. Under the old compounding setup, you'd complete a questionnaire, get sign-off from a licensed physician, and then receive your GLP for a substantial monthly fee. Should they stick with that approach, they'd sell peptides at whatever price the market tolerates. It creates the appearance of legitimacy through a medical pathway. What you're buying is identical to what grey offers, only wrapped in a more recognized or mainstream process. I'd expect COAs to be part of the package. My guess is this approach will draw in the suburban Kens and Karens with cash to spare who feel more comfortable buying that way, rather than those of us who've researched peptides and the grey market ourselves.
